17 May Inclusion of SNPsig® SARS-CoV-2 PCR genotyping portfolio in the NHS England Framework and expansion of SNPsig® product range
Paris, France and Camberley, UK – 17 May 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that the Company’s SNPsig® SARS-CoV-2 polymerase chain reaction (PCR) genotyping portfolio has been included in the NHS England Framework for detecting Variants of Concern (VoC). Novacyt also announces the launch of two new PCR assays to detect SARS-CoV-2 VoC.